CASP3 and neoplasm: Additionally, it was found that administering the synthetic FXR agonist GW4064 simultaneously with oxaliplatin could have a synergistic anti-tumor impact, as GW4064 enhanced the chemosensitivity of cells to oxaliplatin by inducing BAX/caspase-3/GSDME-mediated pyroptosis [136].